



## Current and Upcoming Diagnostics and Prognostics in Multiple Myeloma

Guest Editor:

**Dr. Fredrik Schjesvold**

1. Oslo Myeloma Center, Oslo  
University Hospital, Oslo, Norway  
2. KG Jebsen Center for B Cell  
Malignancies, University of Oslo,  
Oslo, Norway

Deadline for manuscript  
submissions:

**closed (28 February 2023)**

### Message from the Guest Editor

Dear colleagues,

The development of diagnostic and prognostic procedures in multiple myeloma is progressing with significant pace, giving deeper and more substantial information for myeloma patients. The genetic constitution of the clonal plasma cells, analyzed from bone marrow, circulating cells and DNA, as well as the increased information from developing radiological and nuclear-medicine methods, will enable more personalized treatment and follow-up in the future. Our methods of follow-up are also advancing, with more sensitive techniques of measuring minimal residual disease (MRD) laying the ground for studies intensifying and de-intensifying treatment according to the response status of the patient.

In this Special Issue, we trail the current and future statuses of these topics, showing where we are and where we are going.

Dr. Fredrik Schjesvold  
*Guest Editor*

